{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:17:22Z","timestamp":1750220242873,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":18,"publisher":"ACM","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,29]]},"DOI":"10.1145\/3498731.3498749","type":"proceedings-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T16:18:17Z","timestamp":1643213897000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review of National Drug Negotiations"],"prefix":"10.1145","author":[{"given":"Jiayu","family":"Gu","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, China"}]}],"member":"320","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"e_1_3_2_1_1_1","first-page":"464","volume-title":"Progress on drug pricing negotiations in China.\u00a0BioScience Trends, 13(6)","author":"TANG M.","unstructured":"TANG , M. , SONG , P. and HE , J. 2019. Progress on drug pricing negotiations in China.\u00a0BioScience Trends, 13(6) , pp. 464 - 468 . TANG, M., SONG, P. and HE, J. 2019. Progress on drug pricing negotiations in China.\u00a0BioScience Trends, 13(6), pp.464-468."},{"key":"e_1_3_2_1_2_1","unstructured":"FAN C. WANG L. and WU J. 2020. Discussion on improving the access of innovative drugs under the background of dynamic adjustment of medical insurance catalogue. China Health Insurance (05):63-67.  FAN C. WANG L. and WU J. 2020. Discussion on improving the access of innovative drugs under the background of dynamic adjustment of medical insurance catalogue. China Health Insurance (05):63-67."},{"issue":"01","key":"e_1_3_2_1_3_1","first-page":"47","article-title":"Progress and Reflection on the reform of medical insurance payment for innovative drugs in China","volume":"38","author":"WANG H.","year":"2021","unstructured":"WANG , H. , CONG , L. , XIE , C. , WANG , M. , LIU , X. , AND JIN , C. 2021 . Progress and Reflection on the reform of medical insurance payment for innovative drugs in China , Health Economics Research , 38 ( 01 ): 47 - 49 . WANG, H., CONG, L., XIE, C., WANG, M., LIU, X., AND JIN, C. 2021. Progress and Reflection on the reform of medical insurance payment for innovative drugs in China, Health Economics Research ,38(01):47-49.","journal-title":"Health Economics Research"},{"key":"e_1_3_2_1_4_1","unstructured":"The Work Plan for the Adjustment of the National Medical Insurance Drug Catalogue (Draft for Comments) 2020. National Healthcare Security Administration China.  The Work Plan for the Adjustment of the National Medical Insurance Drug Catalogue (Draft for Comments) 2020. National Healthcare Security Administration China."},{"issue":"08","key":"e_1_3_2_1_5_1","first-page":"16","article-title":"Decryption of national drug negotiations","volume":"2","author":"ZHANG M.","year":"2017","unstructured":"ZHANG , M. 2017 . Decryption of national drug negotiations . China Social Security , 2 ( 08 ): 16 - 19 . ZHANG, M. 2017. Decryption of national drug negotiations. China Social Security, 2(08):16-19.","journal-title":"China Social Security"},{"key":"e_1_3_2_1_6_1","unstructured":"YU X. 2018. National Medical Insurance Bureau: the introduction of anticancer drugs into medical insurance will be implemented by the end of November. Beijing News Today. http:\/\/www.myzaker.com\/article\/5bbf494c77ac644863233705  YU X. 2018. National Medical Insurance Bureau: the introduction of anticancer drugs into medical insurance will be implemented by the end of November. Beijing News Today. http:\/\/www.myzaker.com\/article\/5bbf494c77ac644863233705"},{"key":"e_1_3_2_1_7_1","unstructured":"YU X. 2018. National Medical Insurance Bureau: the introduction of anticancer drugs into medical insurance will be implemented by the end of November. Beijing News Today. http:\/\/www.myzaker.com\/article\/5bbf494c77ac644863233705  YU X. 2018. National Medical Insurance Bureau: the introduction of anticancer drugs into medical insurance will be implemented by the end of November. Beijing News Today. http:\/\/www.myzaker.com\/article\/5bbf494c77ac644863233705"},{"key":"e_1_3_2_1_8_1","unstructured":"Seven key points of drug price negotiation of National Health Commission of the People's Republic of China. 2015. YIYAO XINWEN PINDAO. http:\/\/www.zbsjw.cn\/news\/news-show-20150320000008.html  Seven key points of drug price negotiation of National Health Commission of the People's Republic of China. 2015. YIYAO XINWEN PINDAO. http:\/\/www.zbsjw.cn\/news\/news-show-20150320000008.html"},{"key":"e_1_3_2_1_9_1","unstructured":"Policy Interpretation of \u201cNotice of the Ministry of human resources and social security of the state medical insurance administration on printing and distributing the catalogue of drugs for national basic medical insurance industrial injury insurance and maternity insurance (2020).\u201d 2020. National Healthcare Security Administration China.  Policy Interpretation of \u201cNotice of the Ministry of human resources and social security of the state medical insurance administration on printing and distributing the catalogue of drugs for national basic medical insurance industrial injury insurance and maternity insurance (2020).\u201d 2020. National Healthcare Security Administration China."},{"key":"e_1_3_2_1_10_1","volume-title":"Thoughts on the special negotiation on medical insurance access of national antitumor drugs","author":"DING J.","year":"2018","unstructured":"DING , J. 2018. Thoughts on the special negotiation on medical insurance access of national antitumor drugs in 2018 . China Health Insurance, Health Reform Policy Review . https:\/\/www.sohu.com\/a\/259082436_439958 DING, J. 2018. Thoughts on the special negotiation on medical insurance access of national antitumor drugs in 2018. China Health Insurance, Health Reform Policy Review. https:\/\/www.sohu.com\/a\/259082436_439958"},{"key":"e_1_3_2_1_11_1","unstructured":"Official interpretation of medical insurance negotiation in 2019 by the National Medical Insurance Bureau. 2019. National Healthcare Security Administration China. https:\/\/news.yaozh.com\/archive\/27791.html  Official interpretation of medical insurance negotiation in 2019 by the National Medical Insurance Bureau. 2019. National Healthcare Security Administration China. https:\/\/news.yaozh.com\/archive\/27791.html"},{"volume-title":"Analysis of the key mechanism of","author":"DING J.","key":"e_1_3_2_1_12_1","unstructured":"DING , J. , WU , Y. , LI , J. , LI Y. , AND LI , W. 2020. Analysis of the key mechanism of volume price agreement after the access of innovative drug medical insurance\u2014Based on the practice of typical countries and parts of China. China Health Insurance, (07):75- 80 . DING, J., WU, Y., LI, J., LI Y., AND LI, W. 2020. Analysis of the key mechanism of volume price agreement after the access of innovative drug medical insurance\u2014Based on the practice of typical countries and parts of China. China Health Insurance, (07):75-80."},{"key":"e_1_3_2_1_13_1","unstructured":"LIAO Z. 2020. Suggestions on solving the problem of drug use guarantee for patients with rare diseases. China Human Resources and Social Security (06):59.  LIAO Z. 2020. Suggestions on solving the problem of drug use guarantee for patients with rare diseases. China Human Resources and Social Security (06):59."},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"crossref","unstructured":"Kim S Lee JH. 2020. Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction.\u00a0Healthcare (Basel) 8(3):233.  Kim S Lee JH. 2020. Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction.\u00a0Healthcare (Basel) 8(3):233.","DOI":"10.3390\/healthcare8030233"},{"key":"e_1_3_2_1_15_1","unstructured":"The Pew Charitable Trusts. 2017. Payment Policies to Manage Pharmaceutical Costs. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/reports\/2017\/03\/payment-policies-to-manage-pharmaceutical-costs  The Pew Charitable Trusts. 2017. Payment Policies to Manage Pharmaceutical Costs. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/reports\/2017\/03\/payment-policies-to-manage-pharmaceutical-costs"},{"volume-title":"Analysis of the key mechanism of","author":"DING J.","key":"e_1_3_2_1_16_1","unstructured":"DING , J. , WU , Y. , LI , J. , LI Y. , AND LI , W. 2020. Analysis of the key mechanism of volume price agreement after the access of innovative drug medical insurance\u2014\u2014Based on the practice of typical countries and parts of China. China Health Insurance, (07):75- 80 . DING, J., WU, Y., LI, J., LI Y., AND LI, W. 2020. Analysis of the key mechanism of volume price agreement after the access of innovative drug medical insurance\u2014\u2014Based on the practice of typical countries and parts of China. China Health Insurance, (07):75-80."},{"issue":"06","key":"e_1_3_2_1_17_1","first-page":"25","article-title":"A comparative study of the international experience of drug price negotiation and domestic practice","volume":"10","author":"NIU R.","year":"2017","unstructured":"NIU , R. , LIU , Y. , XIANG , Y. , FENG , B. 2017 . A comparative study of the international experience of drug price negotiation and domestic practice . Chinese Journal of Health Policy , 10 ( 06 ): 25 - 32 . NIU, R., LIU, Y., XIANG, Y., FENG, B. 2017. A comparative study of the international experience of drug price negotiation and domestic practice. Chinese Journal of Health Policy, 10(06):25-32.","journal-title":"Chinese Journal of Health Policy"},{"issue":"03","key":"e_1_3_2_1_18_1","first-page":"93","article-title":"A study on the policy of guaranteeing rare diseases and the guarantee model of supply of orphan drugs in Jiangsu Province","volume":"14","author":"JIN M.","year":"2019","unstructured":"JIN , M. , MA , A. 2019 . A study on the policy of guaranteeing rare diseases and the guarantee model of supply of orphan drugs in Jiangsu Province . China Journal of Pharmaceutical Economics , 14 ( 03 ): 93 - 101 . JIN, M., MA, A. 2019. A study on the policy of guaranteeing rare diseases and the guarantee model of supply of orphan drugs in Jiangsu Province. China Journal of Pharmaceutical Economics,14(03):93-101.","journal-title":"China Journal of Pharmaceutical Economics"}],"event":{"name":"ICBBS 2021: 2021 10th International Conference on Bioinformatics and Biomedical Science","acronym":"ICBBS 2021","location":"Xiamen China"},"container-title":["2021 10th International Conference on Bioinformatics and Biomedical Science"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3498731.3498749","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3498731.3498749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:30:29Z","timestamp":1750188629000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3498731.3498749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":18,"alternative-id":["10.1145\/3498731.3498749","10.1145\/3498731"],"URL":"https:\/\/doi.org\/10.1145\/3498731.3498749","relation":{},"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"2022-01-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}